南方财经3月17日电,艾美疫苗公告,预计公司2024年录得收入12.5亿至13亿之间,较上一年度增加5%至9%;净亏损介乎人民币2.5亿元至2.9亿元之间,减亏幅度85%至87%。减亏主要原因是大额资产减值损失金额减少,以及由乙肝疫苗带动的收入增加。
(文章来源:南方财经网)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.